Non Small Cell Lung Cancer Clinical Trial
— TARGETOfficial title:
A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC
Verified date | March 2021 |
Source | Endocyte |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will test the activity of single-agent EC145 and the combination of EC145 plus docetaxel against the current standard docetaxel in second line Non Small Cell Lung Cancer (NSCLC) (adenocarcinoma, squamous, adenosquamous or adenocarcinoma with other NSCLC variants of the lung) in participants with all target lesions expressing the folate receptor [FR(++)].
Status | Completed |
Enrollment | 203 |
Est. completion date | August 2015 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Ability to sign an approved informed consent form (ICF). 2. Must be = 18 years of age. 3. Histology confirmed diagnosis of non-small cell lung cancer (adenocarcinoma, squamous, adenosquamous, or adenocarcinoma with other NSCLC variants of the lung) (Stage IIIB or IV). 4. All (RECIST v1.1-defined) target lesions positive for the folate receptor [FR(++)] by SPECT scan. 5. Only one prior systemic therapy for advanced disease (e.g.,a platinum doublet or a maintenance regimen that includes a platinum doublet; in addition, the participant may have received an epidermal growth factor receptor [EGFR] inhibitor). 6. Radiological evaluation conducted no more than 28 days prior to beginning study therapy. If history of CNS metastasis baseline radiological imaging must include brain MRI or CT. 7. Radiologic evidence of disease progression following the most recent prior treatment. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 9. Must have recovered (to baseline/stabilization) from prior cytotoxic-therapy-associated acute toxicities. 10. Prior radiation therapy is allowed if the following criteria is met: - Radiation to < 25% of the bone marrow; whole pelvis radiation is excluded. - Prior radiotherapy must be completed at least 2 weeks before randomization. - Must have recovered from the acute toxic effects of the treatment before randomized. - Prior thoracic radiation must be completed 30 days before study enrollment. - Irradiated pulmonary lesions cannot be used as target or non-target lesions (and must be excluded) unless there is previous documented progression of these lesions. - Palliative extrathoracic radiotherapy can continue, but these lesions must be excluded as target and non-target lesions. 11. Adequate organ function: - Bone marrow reserve: Absolute neutrophil count (ANC) = 1.5 x 109/L. Platelets = 100 x 109/L. Hemoglobin = 9 g/dL. - Hepatic: Total bilirubin = 1.5 x the upper limit of normal (ULN). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), and lactate dehydrogenase (LDH) and alkaline phosphatase = 2.5 x ULN. - Renal: Serum creatinine = 1.5 x ULN, or for participants with serum creatinine > 1.5 ULN, creatinine clearance = 50 mL/min/1.73 m2 (50mL/min/1.73m2 is equivalent to 0.83 mL/s/m2). 12. Participants of childbearing potential: - Women who are capable of becoming pregnant must have a negative serum pregnancy test within 1 week prior to exposure to EC20 and within 1 week prior to exposure to treatment with EC145 and/or docetaxel. - Women who are capable of becoming pregnant and male participants who are sexually active must practice an effective method of birth control for the duration of their participation in the trial through 3 months following the last dose of EC145 and through 6 months following the last dose of docetaxel. Exclusion Criteria: 1. Prior therapy with docetaxel, vinorelbine, or vinca-containing compounds. 2. Known hypersensitivity to docetaxel or polysorbate 80. 3. Symptomatic central nervous system (CNS) metastases or metastases that result in midline shift, significant edema. 4. Malignancies other than NSCLC that are expected to alter life expectancy or may interfere with disease assessment. Patients with adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or low-grade (Gleason score = 6) localized prostate cancer and patients with prior history of malignancy who have been disease free for more than 3 years are eligible. 5. Serious cardiac illness or medical conditions such as unstable angina, pulmonary embolism, or uncontrolled hypertension. 6. Anti-folate therapy such as methotrexate for rheumatoid arthritis. 7. Baseline peripheral neuropathy CTCAE = Grade 2. 8. Pregnant or lactating women. 9. Other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy. 10. Active infections (e.g., hepatitis or HIV carriers) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Endocyte |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression free survival(PFS)based on investigator assessment using RECIST v1.1 | Disease assessment will be conducted via CT/ MRI every 6 weeks while on study. Participants who come off study due to any other reason except progression of disease or death will be followed via CT/ MRI every 6 weeks until disease progression or until start of new therapy. | From date of baseline disease assessment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 26 months | |
Secondary | Compare overall response rate of participants between treatment arms. | Analysis will occur when approximately 50% of the PFS events have occurred (for each comparison) and when 94 PFS events have occurred. | up to 26 months | |
Secondary | Compare disease control rate of participants between treatment arms. | Analysis will occur when approximately 50% of the PFS events have occurred (for each comparison) and when 94 PFS events have occurred. | up to 26 months | |
Secondary | Compare duration of response of participants between treatment arms. | Analysis will occur when approximately 50% of the PFS events gave occurred (for each comparison) and when 94 PFS events have occurred. | up to 26 months | |
Secondary | Compare duration of disease control of participants between treatment arms. | Analysis will occur when approximately 50% of the PFS events gave occurred (for each comparison) and when 94 PFS events have occurred. | up to 26 months | |
Secondary | Compare overall survival of participants between treatment arms. | Analysis will occur when approximately 50% of the PFS events gave occurred (for each comparison) and when 94 PFS events have occurred. | up to 26 months | |
Secondary | Incidence of Adverse Events, Serious Adverse Events, and Deaths. | Adverse events (as a measure of safety and tolerability) will be assessed at each study visit. | up to 26 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 |